3-(7-bromo-1-benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene | 791041-15-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 3-(7-bromo-1-benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene
• CAS: 791041-15-1
• 化学式: C₁₅H₁₄BrNO
• 分子量: 304.186
• InChiKey: YZCWHHFUBMQIKE-UHFFFAOYSA-N

物化性质

• 沸点：
  417.4±33.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  16.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(7-bromo-1-benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene 在 氨 、 copper dichloride 作用下， 以 甲醇 、 水 为溶剂， 反应 48.0h， 生成 [2-(1-azabicyclo[2.2.2]oct-2-en-3-yl)-1-benzofuran-7-yl]amine
  参考文献：
  名称：

  [EN] NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER
  [FR] NOUVEAUX DERIVES DE BENZOFURANE, POUVANT ETRE UTILISES DANS LA PROPHYLAXIE OU LE TRAITEMENT DES AFFECTIONS ASSOCIEES AU RECEPTEUR DE 5-HT6

  摘要：

  本发明涉及公式（I）的化合物：其中P、R3、W1和W2如本文所述，以及包含这些化合物的药物组合物，用于它们的制备过程，以及用于制备针对5-HT6受体相关疾病的药物的化合物的用途。

  公开号：

  WO2005058858A1
• 作为产物：
  描述：

  3-乙炔基奎宁环-3-醇 在 吡啶 、 copper(I) oxide 、 甲酸 作用下， 反应 12.0h， 生成 3-(7-bromo-1-benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene
  参考文献：
  名称：

  3-(2-Benzofuranyl)quinuclidin-2-ene Derivatives:  Novel Muscarinic Antagonists

  摘要：

  A series of 26 derivatives of the novel muscarinic antagonist 3-(2-benzofuranyl) quinuclidin-2-ene (1) has been synthesized and evaluated for muscarinic and antimuscarinic properties. The affinity of the compounds was determined by competition experiments in homogenates of cerebral cortex, heart, parotid gland, and urinary bladder from guinea pigs using (-)-[H-3]-3-quinuclidinyl benzilate as the radioligand, and the antimuscarinic potency was determined in a functional assay on isolated guinea pig urinary bladder using carbachol as the agonist. The 5-fluorobenzofuranyl derivative was slightly more potent than 1. The 7-bromo-substituted 8 displayed a 14-fold tissue selectivity ratio for muscarinic receptors in the cortex versus the parotid gland. Comparative molecular field analysis and quantitative structure-activity relationship models were developed for this series of substituted benzofuranyl derivatives.

  DOI：

  10.1021/jm950455c

文献信息

• Compounds
  申请人：Johansson Gary

  公开号：US20060287291A1

  公开（公告）日：2006-12-21

  The present invention relates to compounds of formula (I): wherein P, R 3 , W 1 , and W 2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT 6 receptor-related disorders.

  本发明涉及式(I)的化合物：其中P、R3、W1和W2如此描述，以及包含该化合物的制药组合物，其制备过程，以及用于制备针对5-HT6受体相关疾病的药物的化合物的使用。
• Benzofuran compounds
  申请人：Biovitrum AB

  公开号：US07820675B2

  公开（公告）日：2010-10-26

  The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

  本发明涉及式(I)的化合物：其中P、R3、W1和W2如本文所述，以及包含该化合物的制药组合物、其制备过程，以及该化合物用于制备用于对抗5-HT6受体相关疾病的药物的用途。
• Benzofuran Compounds
  申请人：Johansson Gary

  公开号：US20110015185A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I): wherein P, R 3 , W 1 , and W 2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT 6 receptor-related disorders.

  本发明涉及公式（I）的化合物：其中P，R3，W1和W2如本文所述，以及包含该化合物的制药组合物，其制备过程，以及该化合物用于制备针对5-HT6受体相关疾病的药物的用途。
• US7820675B2
  申请人：——

  公开号：US7820675B2

  公开（公告）日：2010-10-26
• [EN] NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER<br/>[FR] NOUVEAUX DERIVES DE BENZOFURANE, POUVANT ETRE UTILISES DANS LA PROPHYLAXIE OU LE TRAITEMENT DES AFFECTIONS ASSOCIEES AU RECEPTEUR DE 5-HT6
  申请人：BIOVITRUM AB

  公开号：WO2005058858A1

  公开（公告）日：2005-06-30

  The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

  本发明涉及公式（I）的化合物：其中P、R3、W1和W2如本文所述，以及包含这些化合物的药物组合物，用于它们的制备过程，以及用于制备针对5-HT6受体相关疾病的药物的化合物的用途。